Nasdaq GlobeNewswire

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD

Del

MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of Targeted Lung Denervation* (TLD) using the Nuvaira(TM) Lung Denervation System in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The AIRFLOW-2 (NCT#02058459) trial, designed to assess the safety of TLD in patients suffering from moderate to severe COPD at 16 institutions throughout Western Europe, included 82 patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4d6d7093-874c-4cac-b8a4-14c7275b566f

COPD is one of the leading causes of morbidity and mortality worldwide. It is characterized by a persistent airflow limitation due to a progressive narrowing of the airways interfering with normal breathing that results in shortness of breath (dyspnea), wheezing, chest tightness, and a productive cough.

"Completing the first randomized, sham-controlled clinical trial of Targeted Lung Denervation is an important milestone to ensure the integrity of scientific data as Nuvaira works to develop a new treatment option for COPD patients," said Jim Pavliska, vice president of Clinical Affairs at Nuvaira. "We are very pleased with the ongoing feedback from the 16 institutions participating in the AIRFLOW-2 trial, as it is providing key insights into optimizing patient selection and procedure workflow for our upcoming pivotal trial, AIRFLOW-3."

The Nuvaira Lung Denervation System is a catheter-based system used to treat the overactive airway nerves during TLD. It is a one-time bronchoscopic procedure that uses the dNerva(TM) Dual Cooled Radiofrequency catheter to provide ablative therapy that opens obstructed airways to improve breathing, and has the potential to provide lasting, whole-lung improvement in patients with moderate to severe COPD.

"We are encouraged by our experience in the AIRFLOW-2 trial using the Nuvaira System," said Professor Felix Herth, M.D., Ph.D., FCCP, chairman, Division of Pulmonology and Respiratory Care Medicine, Thoraxklink, University of Heidelberg. "Because COPD is a progressive disease that affects millions of people and places a significant financial burden on the system, it is imperative that we find better methods of treatment. This new COPD technology may offer a true breakthrough for patients by providing long-term clinical improvement from a one-time procedure," continued Professor Herth.

"TLD is the first medical procedure that targets the whole lung by bronchoscopically disrupting overactive parasympathetic nerves to promote airway dilatation to make it easier to breathe," said Dirk-Jan Slebos, M.D., Ph.D., study principal investigator, University Medical Center, Groningen, The Netherlands. "Our previous research indicates that using Nuvaira's Lung Denervation System is feasible and safe, and there is evidence for a working therapy. In the current study we compared two groups of COPD patients in a sham-controlled manner to show safety and feasibility while separating treatment effect from any placebo effect. Details of the study will be discussed during the September ERS meeting in Milan, Italy."

About COPD
COPD is the umbrella term used to describe a group of diseases such as small airway disease (chronic bronchitis) and emphysema, characterized by chronic and incompletely reversible airway obstruction that interferes with normal breathing. It is estimated that COPD affects 4 to 10 percent of all adults in European countries and more than 300 million people globally1,2.

Pharmacological treatment is the approach for most patients today. Inhaled drugs are used once or twice daily to relax and temporarily open airways. Other forms of treatment include pulmonary rehabilitation, oxygen administration and surgical intervention. These treatments provide temporary relief. The annual financial burden of lung disease in Europe is €141 billion and COPD accounts for almost half3. In the United States, COPD costs are estimated to be more than $50 billion annually4.

About Nuvaira
Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for use during TLD in January 2016. More information may be found at www.Nuvaira.com.

Institutions Participating in the AIRFLOW-2 Clinical Trial:

Institution Principal Investigator at Site Country
1.  AKH Linz  Bernd Lamprecht, MD  Austria
2.  Otto Wagner Spital  Arschang Valipour, MD**  Austria
3.  CHRU de Lille-Hôpital Calmette  Thierry Perez, MD  France
4.  CHU de Grenoble - Hôpital Michallon  Christoph Pison, MD  France
5.  CHU de Paris - Hôpital Bichat Claude Bernard  Armelle Marceau, MD  France
6.  CHU de Reims - Hôpital Maison Blanche  Gaetan Deslee, MD  France
7.  CHU de Strasbourg - Nouvel Hôpital Civil  Romain Kessler, MD  France
8.  Asklepios-Fachkliniken Munchen Gauting  Wolfgang Gesierich, MD  Germany
9.  Charite-Universitatsmedizin Berlin  Ralf-Harto Huebner, MD  Germany
10. Klinikverbund Kempten Oberallgäu  Christian Schumann, MD  Germany
11. Ruhrlandklinik Essen  Kaid Darwiche, MD  Germany
12. Thoraxklinik Heidelberg  Felix Herth, MD  Germany
13. Universitätsklinikum Bonn  Dirk Skowasch, MD  Germany
14. Academic Medical Center  Peter Bonta, MD  The Netherlands
15. University Medical Center Groningen  Dirk-Jan Slebos, MD**  The Netherlands
16. Royal Brompton & Harefield NHS Foundation Trust  Pallav Shah, MD  United Kingdom

*  Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.

** AIRFLOW-2 Trial Principal Investigators

Nuvaira is a trademark of Nuvaira, Inc.

_____________________________
1 Global Chronic Obstructive Pulmonary Disease Epidemiology and Patient Flow - 2017. Fore Pharma. 
http://www.efanet.org/get-advice/copd 
http://www.efanet.org/get-advice/copd 
4 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

Media Contact:
Shane Gleason
Nuvaira
+1 (703-772-3035)
sgleason@Nuvaira.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

TESARO Announces Data Presentations at ESMO 2018 Congress20.10.2018 07:30Pressemelding

Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019 MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high (MSI-H) endometrial cancer presented during the European Society for Medical Oncology (ESMO) Congress. Blinded, pooled interim safety data from the Phase 3 PRIMA trial of niraparib in patients with first-line ovarian cancer regardless of biomarker status were also presented in a poster discussion session and additional data from the QUADRA trial of niraparib for treatment of late-li

The Navigators Group, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger19.10.2018 22:01Pressemelding

STAMFORD, Conn., Oct. 19, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) (“Navigators” or the “Company”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with its previously announced merger with a direct wholly owned subsidiary (“Merger Sub”) of The Hartford Financial Services Group, Inc. (“The Hartford”), expired at 11:59 p.m. Eastern Time on October 18, 2018. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the merger, which remains subject to other closing conditions in the Agreement and Plan of Merger, dated as of August 22, 2018, by and among the Company, The Hartford and Merger Sub. About Navigators The Navigators Group, Inc. (NASDAQ: NAVG) (“Navigators” or the “Company”) is a global specialty insurance holding company. We provide customized insurance solutions designed to protect clients from the complex risk

ATTO Technology introduces the XstreamCORE® FC 7600 32Gb Fibre Channel to 12Gb SAS Hardware Accelerated Storage Controller19.10.2018 15:00Pressemelding

AMHERST, N.Y., Oct. 19, 2018 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for 30 years, announces availability of the ATTO XstreamCORE® FC 7600 storage controller. ATTO XstreamCORE FC 7600 is a standalone, accelerated storage controller that connects any external SAS device, such as a JBOD of HDDs or SSDs, a RAID array or external tape devices, and presents them isolated to individual hosts or shared over a Fibre Channel SAN fabric. It includes ATTO exclusive technologies, ATTO xCORE hardware acceleration processor and ATTO intelligent Bridging Architecture™, that combine to keep latency astonishingly low at three microseconds. For less than the price of a performance server, XstreamCORE FC 7600 enables up to 64 Fibre Channel connected clients to remotely access and share up to 240 SAS/SATA SSD or HDD devices via JBOD or JBOF at direct attached speeds with consistent, d

Biome Grow Introduces PEI Brand, Red Sands Craft Cannabis Co.19.10.2018 13:30Pressemelding

TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (FSE:6OTA) is pleased to introduce its fifth subsidiary company and brand, Red Sands Craft Cannabis Co. (“Red Sands”). Red Sands is located in Prince Edward Island (PEI) and will service both the local and tourist markets in that province with locally produced and regionally grown cannabis products. The Red Sands Craft Cannabis Co. brand reflects PEI’s iconic red sand beaches and the craft goods and services that are produced locally. Visually, it balances the vibrant, energetic colours with the calm nature that PEI is known for, setting the stage for the tailored cannabis products that Red Sands will offer. Though the smallest Canadian province both in terms of land area and population, with approximately 153,000 residents living on the Island, the province has a robust tourism industry. In 2017, the province set records with more than 1,000,000 overnight stays, by an estimated 1.56 million

CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35Pressemelding

DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.

Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21Pressemelding

BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom